Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up after asunaprevir and/or daclatasvir treatment for chronic hepatitis C
2011-005287-21Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of asunaprevir and daclatasvir in hepatitis C virus infection, sponsored by Bristol Myers Squibb. Primary endpoint: Durability of virologic response. Started Dec 2011; status: completed.
02
Drugs
asunaprevirdaclatasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-005287-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005287-21.